Literature DB >> 10614772

Trp-Lys-Tyr-Met-Val-D-Met is a chemoattractant for human phagocytic cells.

Y S Bae1, Y Kim, Y Kim, J H Kim, P G Suh, S H Ryu.   

Abstract

Trp-Lys-Tyr-Met-Val-D-Met (WKYMVm) is a synthetic peptide that stimulates phosphoinositide (PI) hydrolysis in human leukocytes. The peptide binds to a unique cell surface receptor(s). Recently we had demonstrated that human neutrophils, monocytes, and B lymphocytes express this peptide-specific receptor and that stimulation of human leukocytes with the peptide leads to activation of the oxidative respiratory system and the bactericidal activity of neutrophils or monocytes. In this study we showed that the peptide induces chemotaxis of phagocytic leukocytes and studied the signaling pathway leading to chemotaxis in human monocytes. The peptide-induced monocyte chemotaxis is pertussis toxin (PTX)-sensitive. This fact correlates with the peptide's stimulation of PI hydrolysis and intracellular Ca2+ ([Ca2+]i) release, which is also PTX-sensitive. We demonstrate that the peptide-specific receptor is different from receptor(s) for monocyte chemoattractant protein-1 (MCP-1). We also show that intracellular signaling of WKYMVm leading to monocyte chemotaxis is different from that of MCP-1. The peptide-mediated monocyte chemotaxis is insensitive to protein kinase C (PKC) inhibitor (GF109203X) and butan-1-ol, ruling out PKC and phospholipase D participation in this process. On the other hand, a tyrosine kinase inhibitor (genistein) and RhoA inhibitor (C3 transferase) curtailed the peptide-induced chemotaxis in a concentration-dependent manner, implying the involvement of tyrosine kinase and RhoA, respectively. Treatment of human monocytes with the peptide stimulates tyrosine phosphorylation of several cellular proteins, including p125FAK and Pyk2 and translocation of RhoA from the cytosol to the membrane. We conclude that WKYMVm induces chemotaxis of human phagocytic leukocytes via unique receptors and signaling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10614772     DOI: 10.1002/jlb.66.6.915

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

Review 1.  Expression and signaling of formyl-peptide receptors in the brain.

Authors:  Fabio Cattaneo; Germano Guerra; Rosario Ammendola
Journal:  Neurochem Res       Date:  2010-11-02       Impact factor: 3.996

Review 2.  Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Authors:  Fabio Cattaneo; Melania Parisi; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

3.  A WKYMVm-containing combination elicits potent anti-tumor activity in heterotopic cancer animal model.

Authors:  Sang Doo Kim; Ha Young Lee; Jae Woong Shim; Hak Jung Kim; Suk-Hwan Baek; Brian A Zabel; Yoe-Sik Bae
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

4.  Identification of novel peptides that stimulate human neutrophils.

Authors:  Geon Ho Bae; Ha Young Lee; Young Su Jung; Jae Woong Shim; Sang Doo Kim; Suk-Hwan Baek; Jae Young Kwon; Joon Seong Park; Yoe-Sik Bae
Journal:  Exp Mol Med       Date:  2012-02-29       Impact factor: 8.718

5.  Wnt5a stimulates chemotactic migration and chemokine production in human neutrophils.

Authors:  Young Su Jung; Ha Young Lee; Sang Doo Kim; Joon Seong Park; Jung Kuk Kim; Pann-Ghill Suh; Yoe-Sik Bae
Journal:  Exp Mol Med       Date:  2013-06-14       Impact factor: 8.718

6.  The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis.

Authors:  Sang Doo Kim; Soonil Kwon; Sung Kyun Lee; Minsoo Kook; Ha Young Lee; Ki-Duk Song; Hak-Kyo Lee; Suk-Hwan Baek; Chan Bae Park; Yoe-Sik Bae
Journal:  Exp Mol Med       Date:  2013-09-13       Impact factor: 8.718

7.  Bam32/DAPP1-Dependent Neutrophil Reactive Oxygen Species in WKYMVm-Induced Microvascular Hyperpermeability.

Authors:  Li Hao; Aaron J Marshall; Lixin Liu
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.